跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR-GPC3 T Cells
首页
药物
CAR-GPC3 T Cells
CAR-GPC3 T Cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS
EP 3707160 A1
申请人: THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES
优先权: 2017
CN
EP
US
WO
7 件公开
GPC3 CAR-T CELL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
EP 4121516 A4
申请人: EUTILEX CO LTD
优先权: 2020
CN
EP
US
WO
5 件公开
ORTHOGONAL GPC3 CHIMERIC ANTIGEN RECEPTOR T CELLS
EP 4490174 A4
申请人: SYNTHEKINE INC
优先权: 2022
CN
EP
US
WO
4 件公开
CANCER VACCINE USING COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING CANCER ONSET RISK BY BLOOD-CIRCULATING CANCER CELL DETECTION
EP 4527406 A1
申请人: NAT CANCER CT
优先权: 2022
CN
EP
US
WO
4 件公开
CHIMERIC ANTIGEN RECEPTOR TARGETING GPC-3 AND IMMUNE CELLS EXPRESSING SUCH FOR THERAPEUTIC USES
EP 4547718 A1
申请人: CRISPR THERAPEUTICS AG
优先权: 2022
CN
EP
US
WO
4 件公开
COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA-DELTA -T CELLS FOR TREATMENT OF SOLID TUMORS
EP 3860716 A2
申请人: ADICET BIO INC
优先权: 2018
CN
EP
US
4 件公开
USE OF GPC3 AND GPC3-CAR-T IN DIAGNOSIS AND TREATMENT FOR IDIOPATHIC PULMONARY FIBROSIS
WO 2024207679 A1
申请人: RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
优先权: 2023
CN
WO
3 件公开
GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
US 2023151113 A1
申请人: EUTILEX CO LTD
优先权: 2020
CN
US
2 件公开
ANTIBODY SPECIFIC FOR GPC3 AND USES THEREOF
US 20240018262 A1
申请人: INNOBATION BIO LTD
优先权: 2020
CN
US
2 件公开
GENE-EDITED NATURAL KILLER CELLS
US 20260250634 A1
申请人: CRISPR THERAPEUTICS AG
优先权: 2022
US
WO
2 件公开
第 1 / 4 页
上一页
下一页
药物
反馈